HALO News and Press, Halozyme Therapeutics Inc. From 02/21/19

Halozyme Therapeutics (NASDAQ: HALO ): Q4 GAAP EPS of -$0.01 beats by $0.02 . Revenue of $60.2M (-68.2% Y/Y) beats by $0.45M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an upda...

AAOI , ACIA , ADSW , AL , AMH , ANIK , APPN , ATUS , BEAT , BIDU , BJRI , BMRN , BOOM , BYD , CATM , CBPX , CENX , CHSP , COLD , CUBE , CWST , CZR , DBX , DXCM , EBS , ECOL , ED , ENV , EVRG , EXAS , FIX , FLR , FSLR , GMED , HALO , HCC , HPE , HTGC , ...

Introduction - good things may be happening here I stopped trading or commenting on Alexion ( ALXN ) in the first half of 2017, when there were countless uncertainties. ALXN was around $110 and was sold at a small loss. ALXN closed Wednesday at $125.18, lagging the market ( SPY ) and a major...

SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the fourth quarter 2018 on Thursday, February 21 at 4:30 p.m. E...

BREDA , the Netherlands and GHENT, Belgium and SAN DIEGO , Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's...

Quick Take Anchiano Therapeutics ( ANCN ) intends to raise $35 million in a U.S. IPO, per an amended regulatory filing . The company is developing a single biologic candidate to treat bladder and other cancers. ANCN has had promising trial results, strong existing investor support of th...